Inhibition of Glycogen Synthase Kinase-3β Improves Tolerance to Ischemia in Hypertrophied Hearts

Annals of Thoracic Surgery

Volumn 84, Issue 1, 2007, Pages 126-133

  Barillas, Rodrigo ^a   Friehs, Ingeborg ^a   Cao Danh, Hung ^a   Martinez, Joseph F ^a   del Nido, Pedro J ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 IODOINDIRUBIN 3' MONOXIME; CARDIOPLEGIC AGENT; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; INDIRUBIN; INSULIN; LACTIC ACID; LITHIUM; PROTEIN AKT 1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RABBIT; SIGNAL TRANSDUCTION;

ANIMALS; BODY WEIGHT; GLYCOGEN SYNTHASE KINASE 3; GLYCOLYSIS; HYPERTROPHY, LEFT VENTRICULAR; INDOLES; LACTIC ACID; LITHIUM; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; OXIMES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS;

EID: 34250347187     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.02.015     Document Type: Article

References (43)

1. Friehs I., and del Nido P.J. Increased susceptibility of hypertrophied hearts to ischemic injury. Ann Thorac Surg 75 Suppl (2003) 678-684
2. Allard M.F., Schonekess B.O., Henning S.L., English D.R., and Lopaschuk G.D. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 267 (1994) H742-H750
3. Allard M.F., Henning S.L., Wambolt R.B., Granleese S.R., English D.R., and Lopaschuk G.D. Glycogen metabolism in the aerobic hypertrophied rat heart. Circulation 96 (1997) 676-682
4. Allard M.F., Flint J.D., English J.C., et al. Calcium overload during reperfusion is accelerated in isolated hypertrophied rat hearts. J Mol Cell Cardiol 26 (1994) 1551-1563
5. Anderson P.G., Allard M.F., Thomas G.D., Bishop S.P., and Digerness S.B. Increased ischemic injury but decreased hypoxic injury in hypertrophied rat hearts. Circ Res 67 (1990) 948-959
6. Friehs I., Moran A.M., Stamm C., et al. Impaired glucose transporter activity in pressure-overload hypertrophy is an early indicator of progression to failure. Circulation 100 Suppl 2 (1999) 187-193
7. Friehs I., Stamm C., Cao-Danh H., McGowan F.X., and del Nido P.J. Insulin-like growth factor-1 improves postischemic recovery in hypertrophied hearts. Ann Thorac Surg 72 (2001) 1650-1656
8. Friehs I., Cao-Danh H., Stamm C., Cowan D.B., McGowan F.X., and del Nido P.J. Post-natal increase in insulin-sensitive glucose transporter expression is associated with improved recovery of post-ischemic myocardial function. J Thorac Cardiovasc Surg 126 (2003) 263-271
9. Friehs I., Cao-Danh H., Nathan M., McGowan F.X., and del Nido P.J. Impaired insulin-signaling in hypertrophied hearts contributes to increased susceptibility to ischemic injury. Biochem Biophys Res Comm 331 (2005) 15-22
10. Embi N., Rylatt D.B., and Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependant protein kinase and phosphorylase kinase. Eur J Biochem 107 (1980) 519-527
11. Grimes C.A., and Jope R.S. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Progr Neurobiol 65 (2001) 391-426
12. Plyte S.E., Hughes K., Nikolakaki E., Pulverer B.J., and Woodgett J.R. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta 1114 (1992) 147-162
13. Ross S.E., Erickson R.L., Hemati N., and MacDougald O.A. Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. Mol Cell Biol 19 (1999) 8433-8441
14. Pilcher H.R. The ups and downs of lithium. Nature 425 (2003) 118-120
15. Jope R.S. A bimodal model of the mechanism of action of lithium. Mol Psychiatr 4 (1999) 21-25
16. Kim L., and Kimmel A.R. GSK-3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev 10 (2000) 508-514
17. Li X., Bijur G.N., and Jope R.A. Glycogen synthase kinase-3β, mood stabilizer, and neuroprotection. Bipolar Disord 4 (2002) 137-144
18. Jope R.S., and Johnson G.V.W. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29 (2004) 95-102
19. Sutherland C., Leighton I.A., and Cohen P. Inactivation of glycogen synthase 3-beta by phosphorylation: new kinase connection in insulin and growth-factor signaling. Biochem J 296 (1993) 15-19
20. Clodfelder-Miller B., De Sarno P., Zmijewska A.A., Song L., and Jope R.S. Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. J Biol Chem 280 (2005) 39723-39731
21. Leclerc S., Garnier M., Hoessel R., et al. Indirubins inhibit glycogen synthase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. J Biol Chem 276 (2001) 251-260
22. Moran A.M., Friehs I., Takeuchi K., et al. Non-invasive serial evaluation of myocardial mechanics in pressure overload hypertrophy of rabbit myocardium. Herz 28 (2003) 52-62
23. Ryves W.J., Fryer L., Dale T., and Harwood A.J. An assay for glycogen synthase kinase 3 (GSK-3) for use in crude cell extracts. Anal Biochem 264 (1998) 124-127
24. Gaasch W.H., Zile M.R., Hoshino P.K., Weinberg E.O., Rhodes D.R., and Apstein C.S. Tolerance of the hypertrophic heart to ischemia. Studies in compensated and failing dog hearts with pressure overload hypertrophy. Circulation 81 (1990) 1644-1653
25. Jeremy R.W., Koretsune Y., Marban E., and Becker L.C. Relation between glycolysis and calcium homeostasis in postischemic myocardium. Circ Res 70 (1992) 1180-1190
26. Mallet R.T., Hartman D.A., and Bunger R. Glucose requirement for postischemic recovery of perfused working heart. Eur J Biochem 188 (1990) 481-493
27. Lopaschuk G.D., Wambolt R.B., and Barr R.L. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 264 (1993) 135-144
28. Depre C., Vanoverschelde J.L., and Taegtmeyer H. Glucose for the heart. Circulation 99 (1999) 578-588
29. Barrett E.J., Schwartz R.G., Young L.H., Jacob R., and Zaret B.L. Effect of chronic diabetes on myocardial fuel metabolism and insulin sensitivity. Diabetes 37 (1988) 943-948
30. Paolisso G., Galzerano D., Gambardella A., et al. Left ventricular hypertrophy is associated with a stronger impairment of non-oxidative glucose metabolism in hypertensive patients. Eur J Clin Invest 25 (1995) 529-533
31. Stanley W.C., Hall J.L., Hacker T.A., Hernandez L.A., and Whitesell L.F. Decreased myocardial glucose uptake during ischemia in diabetic swine. Metabolism 46 (1997) 168-172
32. Ryves W.J., and Harwood A.J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Comm 280 (2001) 720-725
33. Chin P.C., Majdzadeh N., and D'Mello S.R. Inhibition of GSK 3β is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 137 (2005) 193-201
34. Eldar-Finkelman H., and Ilouz R. Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and type 2 diabetes treatment. Expert Opin Investig Drugs 12 (2003) 1511-1519
35. Oreña S.J., Torchia A.J., and Garofalo R.S. Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes. J Biol Chem 275 (2000) 15765-15772
36. Tong H., Imahashi K., Steenbergen C., and Murphy E. Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 90 (2002) 377-379
37. Eldar-Finkelman H., and Krebs E.G. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci USA 94 (1997) 9660-9664
38. King L.M., and Opie L.H. Glucose and glycogen utilization in myocardial ischemia. Changes in metabolism and consequences for the myocyte. Mol Cell Biochem 180 (1998) 3-26
39. MacAulay K., Hajduch E., Blair A.S., Coghlan M.P., Smith S.A., and Hundal H.S. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. Eur J Biochem 270 (2003) 3829-3838
40. Oudit G.Y., Sun H., Kerfant B.G., Crackower M.A., Penninger J.M., and Backx P.H. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 37 (2004) 449-471
41. Fujo Y., Ngyen T., Wencker D., Kitsis R.N., and Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101 (2000) 660-667
42. Matsui T., Tao J., del Monte F., et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104 (2001) 330-335
43. Beauloye C., Bertrand L., Krause U., et al. No-flow ischemia inhibits insulin signaling in heart by decreasing intracellular pH. Circ Res 88 (2001) 513-519